BRCA1 and ovarian carcinoma: BRCA1/2 mutation carriers also benefit from PARP inhibitors, and our previous study demonstrated that fluzoparib, a PARP inhibitor, had antitumor activity in BC and ovarian cancer, particularly in BRCA1/2-mutated patients (26).